title: Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
abstract: A series of optically pure 2-[substituted-3-aminopropynyl]pyrrolidine derivatives, which are restricted-rotation analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5, compound 1), have been prepared from d- and l-proline. The compounds when tested in a series of in vitro muscarinic assays [[3H]CD (cortex), [3H]QNB (cortex), [3H]PZ (cortex), [3H]QNB (heart), [3H]QNB + GppNHp (heart)] were found to have weaker muscarinic properties than compound 1. The decrease in affinity was attributed to the increased size of the molecule resulting from the addition of a methylene group to form the pyrrolidine ring. The use of optically active compounds provided a more detailed examination of the complex pharmacological effects of the flexible muscarinic agent 1. The R enantiomers in the acetamide derivatives 12b, 12d, and 12f had a 5-10-fold greater affinity for the muscarinic receptor than the corresponding S enantiomers. A 5-fold difference or less found in the (R)- and (S)-carbamate derivatives 9, 15, and 16 suggested close overlap of the two enantiomers in the receptor binding domain. The affinity differences found in the enantiomeric acetamido derivatives when compared to those of the carbamate analogues may be the result of limited rotation of the acetamido group.
authors: American Cyanamid Company, Lederle Laboratories, Pearl River, New York 10965.
authors: E J
authors: EJ
authors: Trybulski
authors: R H
authors: RH
authors: Kramss
authors: R M
authors: RM
authors: Mangano
authors: A
authors: A
authors: Rusinko
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D002540:Cerebral Cortex / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D004148:Dioxolanes / Q000378:metabolism; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008968:Molecular Conformation; D015394:Molecular Structure; D009206:Myocardium / Q000378:metabolism; D010277:Parasympathomimetics / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D010890:Pirenzepine / Q000378:metabolism; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011976:Receptors, Muscarinic / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D004148:Dioxolanes; D010277:Parasympathomimetics; D011759:Pyrrolidines; D011976:Receptors, Muscarinic; D006165:Guanylyl Imidodiphosphate; D010890:Pirenzepine; C028858:methamilane methiodide; D011813:Quinuclidinyl Benzilate; C038672:N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide